Merck Sharp & Dohme

  • Home
  • Merck Sharp & Dohme
Beyond Keytruda – What does Merck’s future hold?
  • February 7, 2019
  • 0

Sales of Merck Sharp & Dohme's immuno-oncology drug Keytruda grew a massive 66% year-on-year bringing in $2.15bn in the fourth quarter surpassing most analysts expectations.  Earlier in January MSD announced...

Read more

Trending

CHMP endorses six new medicines
  • February 4, 2019
  • 0
NHS
NHS to add 1,000 social prescribers to ease GP load
  • January 30, 2019
  • 0
Janssen
NHS mental health woes
  • January 24, 2019
  • 0
bristol Myers squibb, Celgene
BMS buys Celgene for $76bn
  • January 3, 2019
  • 0
rejected
NICE rejects Novartis’ migraine drug for routine use
  • January 9, 2019
  • 0
brexit
The reality of Brexit’s effect on pharma
  • January 9, 2019
  • 0

Recent Posts

Senate Finance Committee
The great American drug-pricing debacle
  • February 27, 2019
  • 0

Yesterday – Tuesday

The coming age of biosimilars
  • February 26, 2019
  • 0
Novartis acquires game-changing cardiovascular therapy
  • February 25, 2019
  • 0
spark therapeutics
Roche buys gene therapy company Spark for $4.3bn
  • February 25, 2019
  • 0
AbbVie
AbbVie and Voyager Therapeutics in Parkinson’s Pact
  • February 22, 2019
  • 0

Learn more

Copyright © 2021 Pharmascimed. All Rights Reserved.